Jefferson Terry

, MD, PhD, FRCPC

Assistant Professor, Pathology and Molecular Medicine

Division: Anatomical Pathology (Pediatric)
Pediatric Pathologist, McMaster Children’s Hospital

McMaster University
2N17 Hamilton Health Sciences
905-521-2100 ext 76314
jeterry@mcmaster.ca

Education and Professional Standing

• ABP Certification, Pediatric Pathology, Children’s Hospital Boston, 2011
• FRCPC, Anatomical Pathology, University of British Columbia, 2010
• PhD, Pathology, University of British Columbia, 2008
• MD, University of Calgary, 2003

---

Interests

Research Focus

Dr. Terry’s research interests involve areas germane to the clinical practice of pediatric and perinatal pathology. Primary areas of focus include the role of CD133 expressing cancer stem-like cells in the development and maintenance of synovial sarcoma, the characterization of premalignant and malignant melanocytic lesions in neurocristic hamartomas, and the relationship of nascent endothelial marker expression in extravillous trophoblast to histological features of pre-eclampsia and eclampsia.

Clinical Focus

As a member of the pediatric pathology department at McMaster Children’s Hospital, Dr. Terry provides consultative services in pediatric and perinatal anatomical pathology. Dr. Terry’s clinical interests include placental pathology, perinatal autopsy, and tumor pathology.

Academic Interests

Dr. Terry is active in both undergraduate medical education and post-graduate resident teaching.

---

Selected Publications

• Terry J, De Luca A, Leung S, Peacock G, Wang YZ, Elliot WM, Huntsman D. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and non-squamous subtypes. Arch Path Lab Med. 2011;135(4):433-439
• Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal Immunohistochemical Markers for Distinguishing Lung Adenocarcinomas from Squamous Cell Carcinomas in Small Tumor Samples. Am J Surg Pathol. 2010; 34:1805-1811
• Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T, Chuah E, Corbett R, Fejes AP, Griffith M, Yee J, Martin M, Mayo M, Melnyk N, Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliffe M, Tam A, Terry J, Thiessen N, Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG, Birol I, Hirst M, Holt RA, Marra MA Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010; 11:R82
• Terry J, Nielsen TO. Expression of CD133 in Synovial Sarcoma. Appl Immunohistochem Mol Morphol. 2010;18(2):159-165
• Terry J, Torlakovic EE, Garratt J, Miller D, Kobel M, Cooper J, Bahzad S, Pilavdzic D, O’Malley F, O’Brien AE, Sengupta S, Alport E, Tetu B, Knight B, Pettigrew NM, Berendt R, Wobler R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB. Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: an Initiative of Canadian Quality Control in Immunohisto-chemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/ Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2009; 17(5):375-382
• Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007 Feb; 31(2):240-246
• Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO. Hsp90 inhibitor 17-allylamino-17-demethoxygeldana-mycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res. 2005 Aug 1;11(15):5631-5638.
• Terry J, Barry TS Hsu FD, Horsman DE, Huntsman DG, Gown AM, Nielsen TO. Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe. Diagn Mol Pathol. 2005 Jun;14(2):77-82.